Abstract
Results of an international phase 2study of the oral farnesyl transferase inhibitor (FTI) tipifarnib (ZARNESTRA®) in patients with high-risk myelodysplastic syndrome (MDS)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have